TCM
XENE icon

TimesSquare Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

TimesSquare Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3M Buy
451,593
+92,300
+26% +$5.12M 0.4% 85
2026
Q1 		$20.9M Sell
359,293
-173,447
-33% -$7.99M 0.35% 102
2025
Q4 		$23.9M Sell
532,740
-24,060
-4% -$1.01M 0.36% 103
2025
Q3 		$22.4M Sell
556,800
-14,442
-3% -$509K 0.32% 107
2025
Q2 		$17.9M Sell
571,242
-174,309
-23% -$5.69M 0.26% 119
2025
Q1 		$25M Sell
745,551
-103,299
-12% -$3.92M 0.4% 89
2024
Q4 		$33.3M Buy
848,850
+70,557
+9% +$2.92M 0.48% 90
2024
Q3 		$30.6M Buy
778,293
+23,800
+3% +$960K 0.46% 87
2024
Q2 		$29.4M Buy
754,493
+17,320
+2% +$692K 0.46% 87
2024
Q1 		$31.7M Sell
737,173
-56,781
-7% -$2.61M 0.46% 90
2023
Q4 		$36.6M Buy
793,954
+203,379
+34% +$7.19M 0.54% 77
2023
Q3 		$20.2M Buy
590,575
+163,650
+38% +$6.12M 0.31% 116
2023
Q2 		$16.4M Buy
426,925
+19,130
+5% +$760K 0.24% 134
2023
Q1 		$14.6M Sell
407,795
-74,385
-15% -$2.75M 0.21% 144
2022
Q4 		$19M Buy
+482,180
New +$17.6M 0.27% 134

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TimesSquare Capital Management's XENE Position: Q2 2026 in Review

TimesSquare Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 26% in Q2 2026, buying an estimated $5.12M and bringing the position to 451,593 shares worth $27.3M. The position accounts for 0.4% of the portfolio, ranked #85.

TimesSquare Capital Management first reported a position in XENE in Q4 2022 and has held it in 15 quarters since. The position peaked at $36.6M in Q4 2023. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • TimesSquare Capital Management held 451,593 shares of Xenon Pharmaceuticals worth $27.3M as of Q2 2026.
  • TimesSquare Capital Management bought 92,300 Xenon Pharmaceuticals shares in Q2 2026, an estimated $5.12M.
  • Xenon Pharmaceuticals made up 0.4% of TimesSquare Capital Management's portfolio in Q2 2026, its #85 holding.
  • TimesSquare Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • TimesSquare Capital Management's Xenon Pharmaceuticals position peaked at $36.6M in Q4 2023.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on TimesSquare Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.